U.S. markets open in 5 hours 36 minutes
  • S&P Futures

    4,298.50
    -9.25 (-0.21%)
     
  • Dow Futures

    34,076.00
    -42.00 (-0.12%)
     
  • Nasdaq Futures

    13,603.50
    -54.75 (-0.40%)
     
  • Russell 2000 Futures

    2,020.10
    -3.20 (-0.16%)
     
  • Crude Oil

    86.77
    +0.24 (+0.28%)
     
  • Gold

    1,788.50
    -1.20 (-0.07%)
     
  • Silver

    20.00
    -0.08 (-0.42%)
     
  • EUR/USD

    1.0163
    -0.0008 (-0.08%)
     
  • 10-Yr Bond

    2.8240
    0.0000 (0.00%)
     
  • Vix

    19.75
    -0.20 (-1.00%)
     
  • GBP/USD

    1.2098
    +0.0003 (+0.03%)
     
  • USD/JPY

    134.7880
    +0.5730 (+0.43%)
     
  • BTC-USD

    23,864.39
    -139.83 (-0.58%)
     
  • CMC Crypto 200

    569.82
    -2.09 (-0.37%)
     
  • FTSE 100

    7,535.97
    -0.09 (-0.00%)
     
  • Nikkei 225

    29,222.77
    +353.86 (+1.23%)
     

Those who invested in Abiomed (NASDAQ:ABMD) five years ago are up 86%

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Abiomed, Inc. (NASDAQ:ABMD) shareholders might be concerned after seeing the share price drop 10% in the last quarter. While that's not great, the returns over five years have been decent. After all, the stock has performed better than the market (79%) in that time, and is up 86%.

So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.

Check out our latest analysis for Abiomed

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

Over half a decade, Abiomed managed to grow its earnings per share at 20% a year. This EPS growth is higher than the 13% average annual increase in the share price. Therefore, it seems the market has become relatively pessimistic about the company. Of course, with a P/E ratio of 86.82, the market remains optimistic.

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

earnings-per-share-growth
earnings-per-share-growth

Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.

A Different Perspective

The total return of 11% received by Abiomed shareholders over the last year isn't far from the market return of -11%. Longer term investors wouldn't be so upset, since they would have made 13%, each year, over five years. If the stock price has been impacted by changing sentiment, rather than deteriorating business conditions, it could spell opportunity. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 3 warning signs for Abiomed you should be aware of.

We will like Abiomed better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.